quinoxalines has been researched along with delavirdine in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (75.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bender, R; Kirsch, R; Kleim, JP; Meichsner, C; Paessens, A; Riess, G | 1 |
Balzarini, J; De Clercq, E; Dunkler, A; Esnouf, R; Karlsson, A; Kleim, JP; Parniak, MA; Pelemans, H; Vandamme, AM | 1 |
Balzarini, J; De Clercq, E; Kleim, JP; Pelemans, H; Riess, G; Roesner, M; Winkler, I | 1 |
Balzarini, J; Burt, V; Carbonez, A; De Clercq, E; Kleim, JP | 1 |
4 other study(ies) available for quinoxalines and delavirdine
Article | Year |
---|---|
Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase.
Topics: Antiviral Agents; Base Sequence; Benzodiazepines; Benzoxazoles; Delavirdine; DNA Mutational Analysis; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Imidazoles; Indoles; Molecular Sequence Data; Mutagenesis, Site-Directed; Nevirapine; Piperazines; Pyridines; Pyridones; Quinoxalines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Selection, Genetic; Structure-Activity Relationship | 1994 |
Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.
Topics: Amino Acid Substitution; Anti-HIV Agents; Binding Sites; Delavirdine; Drug Resistance, Microbial; Histidine; HIV Reverse Transcriptase; Kinetics; Ligands; Point Mutation; Proline; Quinoxalines; Reverse Transcriptase Inhibitors; Time Factors | 1997 |
Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined
Topics: Anti-HIV Agents; Antiviral Agents; Benzodiazepines; Cell Line; Delavirdine; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Imidazoles; Lamivudine; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mutation; Nevirapine; Quinoxalines; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Anilides; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Nevirapine; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Thioamides; Uracil | 2000 |